[] Genzyme Corporate [] Genzyme Websites
  • Reimbursement Support
  • Have coverage, coding or reimbursement questions? Call
    1-800-982-8292, M–F, 9am-8pm
    (ET).

Ordering Synvisc-One®

Ordering Synvisc-One is easy. Based on the type of insurance your patients have, there are several ways to buy Synvisc-One. If you have questions about insurance coverage, call SYNVISC ConnectionSM at 1-800-982-8292, M–F, 9am–8pm (ET).
Always order genuine Synvisc-One through one of these approved distribution channels and you’ll be assured of getting a safe and effective product.

Ordering Options


For Privately Insured Patients

  • Call Genzyme directly at 1-888-3-SYNVISC (1-888-379-6847), Option #1, M–F, 8am–8pm (ET), to place an order for your office.
  • Contact your wholesaler. Place an order for your office through your wholesale supply house.
  • Order through a Specialty Pharmacy. Order Synvisc-One for specific patients through a pharmacy that coordinates all payments with the insurer. Learn more about the Specialty Pharmacy program and download Specialty Pharmacy Order forms.

For Medicare Patients

For Medicare-eligible patients, you must purchase and stock Synvisc-One in your office or the patient will be responsible for the full product price.

  • Call Genzyme directly at 1-888-3-SYNVISC (1-888-379-6847), Option #1, M–F, 8am–8pm (ET), to place an order for your office. Or fax a completed Synvisc-One Order Form (PDF) to 1-800-698-8979.
  • Contact your wholesaler. Place an order for your office through your wholesale supply house.

For Medicaid Patients


  • Call 1-888-3-SYNVISC (1-888-379-6847), Option #3, M–F, 8am–8pm (ET), for state-specific benefits.

Indication

SYNVISC® (hylan G-F 20) and Synvisc-One® (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non pharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information

SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Use caution when injecting SYNVISC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee to be treated.

Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment. Aspiration of any effusion prior to injection is highly recommended. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc-One have not been established in children or in pregnant or lactating women. It is unknown whether SYNVISC or Synvisc-One is excreted in human milk.

For SYNVISC
In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

View the Complete Prescribing Information for SYNVISC (PDF)

For Synvisc-One
The most commonly reported related local adverse events were transient, mild-to-moderate arthralgia, arthritis, arthropathy, injection site pain and joint effusion. No serious adverse events were reported in clinical trials in knees injected with Synvisc-One. Serious local adverse events have been reported only rarely in post-marketing use.  Repeat treatment did not affect the safety profile. In the pivotal clinical trial, there was one related systemic event of syncope. The most common systemic side effects irrespective of relationship to Synvisc-One were headache, back pain, nasopharyngitis and influenza. Systemic adverse event profiles were similar between patients in the Synvisc-One and Saline Control groups.

View the Complete Prescribing Information for Synvisc-One (PDF)